MYD88 and diffuse large B-cell lymphoma: Notably, a patient with r/r DEL DLBCL and MYD88 mutation, who had previously received two lines of therapy (chidamide combined with R-CHOP, R-ICE), achieved CR with PM treatment, and the CR was sustained for over 18 months (Fig. 6d).